Clinical Trials Logo

Necrobiosis Lipoidica clinical trials

View clinical trials related to Necrobiosis Lipoidica.

Filter by:
  • None
  • Page 1

NCT ID: NCT04800562 Terminated - Clinical trials for Necrobiosis Lipoidica

A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica

Start date: April 12, 2021
Phase: Phase 2
Study type: Interventional

This is a randomized, double blind, placebo controlled study that will evaluate the efficacy and safety of PCS499 as compared to placebo for the treatment of ulcerations of patients with necrobiosis lipoidica (NL) and will inform the design of future studies. Approximately 20 ulcerated NL patients who also meet other inclusion/exclusion criteria will be enrolled in the study. The primary objective of this study is to evaluate the efficacy of PCS499 as compared with placebo in ulcerated patients with Necrobiosis Lipoidica.

NCT ID: NCT04492618 Completed - Clinical trials for Necrobiosis Lipoidica

Ruxolitinib Cream in the Treatment of Cutaneous Necrobiosis Lipoidica

Start date: September 29, 2020
Phase: Phase 2
Study type: Interventional

This research study is evaluating the safety and efficacy of a topical drug treatment "Ruxolitinib" in treating Necrobiosis Lipoidica (NL).

NCT ID: NCT03791060 Terminated - Clinical trials for Necrobiosis Lipoidica Diabeticorum

Secukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD)

Start date: April 3, 2019
Phase: Phase 2
Study type: Interventional

This study investigates the efficacy of secukinumab in necrobiosis lipoidica diabeticorum (NLD).

NCT ID: NCT03698864 Completed - Clinical trials for Necrobiosis Lipoidica

A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica

Start date: November 7, 2018
Phase: Phase 2
Study type: Interventional

This is an open-label study that will evaluate the safety of PCS499 for the treatment of necrobiosis lipoidica (NL) and will inform the design of future studies. Approximately 12 NL patients (6-9 patients without ulceration and 3-6 patients with ulceration) who also meet other inclusion/exclusion criteria will be enrolled in the study. The primary objective of this study is to evaluate the safety and tolerability profile of PCS499 in patients with Necrobiosis Lipoidica.